Metabolomics: Applications and promise in mycobacterial disease

Annals of the American Thoracic Society

Volumn 12, Issue 9, 2015, Pages 1278-1287

  Mirsaeidi, Mehdi ^a   Banoei, Mohammad Mehdi ^b   Winston, Brent W ^b,c   Schraufnagel, Dean E ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Metabolomics; Nontuberculous; Omics; Tuberculosis

Indexed keywords

BIOLOGICAL MARKER;

ANALYTIC METHOD; BIOMICS; DATA ANALYSIS; HUMAN; LIPIDOMICS; MEDICINE; METABOLITE; METABOLOME; METABOLOMICS; MULTIVARIATE ANALYSIS; MYCOBACTERIOSIS; NONHUMAN; PRECISION MEDICINE; PREDICTIVE VALUE; REVIEW; MYCOBACTERIUM INFECTIONS; PERSONALIZED MEDICINE; PROCEDURES;

BIOMARKERS; HUMANS; METABOLOMICS; MYCOBACTERIUM INFECTIONS; PRECISION MEDICINE;

EID: 84942274746     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201505-279PS     Document Type: Review

References (72)

1. Mirsaeidi M, Farshidpour M, Ebrahimi G, Aliberti S, Falkinham JO III. Management of nontuberculous mycobacterial infection in the elderly. Eur J Intern Med 2014; 25: 356-363.
2. van Ingen J. Diagnosis of nontuberculous mycobacterial infections. Semin Respir Crit Care Med 2013; 34: 103-109.
3. Ge Y, Wang TJ. Identifying novel biomarkers for cardiovascular disease risk prediction. J Intern Med 2012; 272: 430-439.
4. Davis VW, Schiller DE, Eurich D, Sawyer MB. Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. World J Surg Oncol 2012; 10: 271.
5. Farshidfar F, Weljie AM, Kopciuk K, Buie WD, Maclean A, Dixon E, Sutherland FR, Molckovsky A, Vogel HJ, Bathe OF. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med 2012; 4: 42.
6. Ho WE, Xu YJ, Xu F, Cheng C, Peh HY, Tannenbaum SR, Wong WS, Ong CN. Metabolomics reveals altered metabolic pathways in experimental asthma. Am J Respir Cell Mol Biol 2013; 48: 204-211.
7. Ubhi BK, Riley JH, Shaw PA, Lomas DA, Tal-Singer R, MacNee W, Griffin JL, Connor SC. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J 2012; 40: 345-355.
8. Weiner J III, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, Mohney RP, Arndt-Sullivan C, Ganoza CA, Faé KC, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 2012; 7: E40221.
9. Mickiewicz B, Vogel HJ, Wong HR, Winston BW. Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality. Am J Respir Crit Care Med 2013; 187: 967-976.
10. Mickiewicz B, Duggan GE, Winston BW, Doig C, Kubes P, Vogel HJ; Alberta Sepsis Network. Metabolic profiling of serum samples by 1H nuclear magnetic resonance spectroscopy as a potential diagnostic approach for septic shock. Crit Care Med 2014; 42: 1140-1149.
11. Ghannoum MA, Mukherjee PK, Jurevic RJ, Retuerto M, Brown RE, Sikaroodi M, Webster-Cyriaque J, Gillevet PM. Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: Toward novel diagnostic targets. OMICS 2013; 17: 5-15.
12. Philippeos C, Steffens FE, Meyer D. Comparative 1H NMR-based metabonomic analysis of HIV-1 sera. J Biomol NMR 2009; 44: 127-137.
13. Nicholson JK, Lindon JC, Holmes E. "Metabonomics": Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29: 1181-1189.
14. Villas-Bôas SG, Mas S, Akesson M, Smedsgaard J, Nielsen J. Mass spectrometry in metabolome analysis. Mass Spectrom Rev 2005; 24: 613-646.
15. Tang J. Microbial metabolomics. Curr Genomics 2011; 12: 391-403.
16. Heijne WH, Kienhuis AS, van Ommen B, Stierum RH, Groten JP. Systems toxicology: Applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev Proteomics 2005; 2: 767-780.
17. Oliver SG, Winson MK, Kell DB, Baganz F. Systematic functional analysis of the yeast genome. Trends Biotechnol 1998; 16: 373-378.
18. Fell DA. Enzymes, metabolites and fluxes. J Exp Bot 2005; 56: 267-272.
19. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008; 48: 653-683.
20. Collino S, Martin FP, Rezzi S. Clinical metabolomics paves the way towards future healthcare strategies. Br J Clin Pharmacol 2013; 75: 619-629.
21. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: The roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011; 40: 387-426.
22. van Ravenzwaay B, Cunha GC, Leibold E, Looser R, Mellert W, Prokoudine A, Walk T, Wiemer J. The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 2007; 172: 21-28.
23. Davis VW, Bathe OF, Schiller DE, Slupsky CM, Sawyer MB. Metabolomics and surgical oncology: Potential role for small molecule biomarkers. J Surg Oncol 2011; 103: 451-459.
24. Lindon JC, Holmes E, Nicholson JK. So what's the deal with metabonomics? Anal Chem 2003; 75: 384A-391A.
25. Banoei MM, Donnelly SJ, Mickiewicz B, Weljie A, Vogel HJ, Winston BW. Metabolomics in critical care medicine: A new approach to biomarker discovery. Clin Invest Med 2014; 37: E363-E376.
26. Junot C, Fenaille F, Colsch B, Bécher F. High resolution mass spectrometry based techniques at the crossroads of metabolic pathways. Mass Spectrom Rev 2014; 33: 471-500.
27. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, et al. The human serum metabolome. PLoS One 2011; 6: E16957.
28. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: A platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1: 153-161.
29. Lindon JC, Holmes E, Nicholson JK. Metabonomics techniques and applications to pharmaceutical research and development. Pharm Res 2006; 23: 1075-1088.
30. Johnson CH, Gonzalez FJ. Challenges and opportunities of metabolomics. J Cell Physiol 2012; 227: 2975-2981.
31. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007; 6: 469-479.
32. Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikström C, Wold S. Multi-And megavariate data analysis. I. Basic principles and applications. Umeå, Sweden: Umetrics AB; 2006.
33. Ebbels TMD, Cavill R. Bioinformatic methods in NMR-based metabolic profiling. Prog Nucl Magn Reson Spectrosc 2009; 55: 361-374.
34. Pacchiarotta T, Deelder AM, Mayboroda OA. Metabolomic investigations of human infections. Bioanalysis 2012; 4: 919-925.
35. Kruh-Garcia NA, Wolfe LM, Dobos KM. Deciphering the role of exosomes in tuberculosis. Tuberculosis (Edinb) 2015; 95: 26-30.
36. Chow ED, Cox JS. TB lipidomics-The final frontier. Chem Biol 2011; 18: 1517-1518.
37. Layre E, Moody DB. Lipidomic profiling of model organisms and the world's major pathogens. Biochimie 2013; 95: 109-115.
38. Jain M, Petzold CJ, Schelle MW, Leavell MD, Mougous JD, Bertozzi CR, Leary JA, Cox JS. Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids via metabolic coupling. Proc Natl Acad Sci USA 2007; 104: 5133-5138.
39. Mahrous EA, Lee RB, Lee RE. A rapid approach to lipid profiling of mycobacteria using 2D HSQC NMR maps. J Lipid Res 2008; 49: 455-463.
40. Portevin D, Sukumar S, Coscolla M, Shui G, Li B, Guan XL, Bendt AK, Young D, Gagneux S, Wenk MR. Lipidomics and genomics of Mycobacterium tuberculosis reveal lineage-specific trends in mycolic acid biosynthesis. MicrobiologyOpen 2014; 3: 823-835.
41. du Preez I, Loots DT. New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa. Tuberculosis (Edinb) 2013; 93: 330-337.
42. Schoeman JC, du Preez I, Loots T. A comparison of four sputum preextraction preparation methods for identifying and characterising Mycobacterium tuberculosis using GCxGC-TOFMS metabolomics. J Microbiol Methods 2012; 91: 301-311.
43. Cha D, Cheng D, Liu M, Zeng Z, Hu X, Guan W. Analysis of fatty acids in sputum from patients with pulmonary tuberculosis using gas chromatography-mass spectrometry preceded by solid-phase microextraction and post-derivatization on the fiber. J Chromatogr A 2009; 1216: 1450-1457.
44. O'Sullivan DM, Nicoara SC, Mutetwa R, Mungofa S, Lee OY, Minnikin DE, Bardwell MW, Corbett EL, McNerney R, Morgan GH. Detection of Mycobacterium tuberculosis in sputum by gas chromatographymass spectrometry of methyl mycocerosates released by thermochemolysis. PLoS One 2012; 7: E32836.
45. Loots T. An altered Mycobacterium tuberculosis metabolome induced by katG mutations resulting in isoniazid resistance. Antimicrob Agents Chemother 2014; 58: 2144-2149.
46. Bisson GP, Mehaffy C, Broeckling C, Prenni J, Rifat D, Lun DS, Burgos M, Weissman D, Karakousis PC, Dobos K. Upregulation of the phthiocerol dimycocerosate biosynthetic pathway by rifampinresistant, rpoB mutant Mycobacterium tuberculosis. J Bacteriol 2012; 194: 6441-6452.
47. Frediani JK, Jones DP, Tukvadze N, Uppal K, Sanikidze E, Kipiani M, Tran VT, Hebbar G, Walker DI, Kempker RR, et al. Plasma metabolomics in human pulmonary tuberculosis disease: A pilot study. PLoS One 2014; 9: E108854.
48. Al-Mubarak R, Vander Heiden J, Broeckling CD, Balagon M, Brennan PJ, Vissa VD. Serum metabolomics reveals higher levels of polyunsaturated fatty acids in lepromatous leprosy: Potential markers for susceptibility and pathogenesis. PLoS Negl Trop Dis 2011; 5: E1303.
49. Feng S, Du YQ, Zhang L, Zhang L, Feng RR, Liu SY. Analysis of serum metabolic profile by ultra-performance liquid chromatography-mass spectrometry for biomarkers discovery: Application in a pilot study to discriminate patients with tuberculosis. Chin Med J (Engl) 2015; 128: 159-168.
50. Dang NA, Janssen HG, Kolk AH. Rapid diagnosis of TB using GC-MS and chemometrics. Bioanalysis 2013; 5: 3079-3097.
51. Azuaje F. Bioinformatics and biomarker discovery. Hoboken, NJ: Wiley-Blackwell; 2010.
52. Ottenhoff TH, Ellner JJ, Kaufmann SH. Ten challenges for TB biomarkers. Tuberculosis (Edinb) 2012; 92: S17-S20.
53. De Buck J, Shaykhutdinov R, Barkema HW, Vogel HJ. Metabolomic profiling in cattle experimentally infected with Mycobacterium avium subsp. paratuberculosis. PLoS One 2014; 9: E111872.
54. Sebina I, Biraro IA, Dockrell HM, Elliott AM, Cose S. Circulating B-lymphocytes as potential biomarkers of tuberculosis infection activity. PLoS One 2014; 9: E106796.
55. Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, Schito M, Zumla A. Tuberculosis biomarkers discovery: Developments, needs, and challenges. Lancet Infect Dis 2013; 13: 362-372.
56. Shin JH, Yang JY, Jeon BY, Yoon YJ, Cho SN, Kang YH, Ryu H, Hwang GS. 1H NMR-based metabolomic profiling in mice infected with Mycobacterium tuberculosis. J Proteome Res 2011; 10: 2238-2247.
57. Mirsaeidi M, Farshidpour M, Allen MB, Ebrahimi G, Falkinham JO. Highlight on advances in nontuberculous mycobacterial disease in North America. Biomed Res Int 2014; 2014: 919474.
58. Gieger C, Geistlinger L, Altmaier E, Hrabéde Angelis M, Kronenberg F, Meitinger T, Mewes HW, Wichmann HE, Weinberger KM, Adamski J, et al. Genetics meets metabolomics: A genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008; 4: E1000282.
59. Mahapatra S, Hess AM, Johnson JL, Eisenach KD, DeGroote MA, Gitta P, Joloba ML, Kaplan G, Walzl G, Boom WH, et al. A metabolic biosignature of early response to anti-Tuberculosis treatment. BMC Infect Dis 2014; 14: 53.
60. Nicholson JK, Holmes E, Elliott P. The metabolome-wide association study: A new look at human disease risk factors. J Proteome Res 2008; 7: 3637-3638.
61. Rezzi S, Martin FP, Kochhar S. Defining personal nutrition and metabolic health through metabonomics. Ernst Schering Found Symp Proc 2007; 4: 251-264.
62. Antoniewicz MR, Kelleher JK, Stephanopoulos G. Accurate assessment of amino acid mass isotopomer distributions for metabolic flux analysis. Anal Chem 2007; 79: 7554-7559.
63. Halouska S, Fenton RJ, Zinniel DK, Marshall DD, Barletta RG, Powers R. Metabolomics analysis identifies D-Alanine-D-Alanine ligase as the primary lethal target of D-cycloserine in mycobacteria. J Proteome Res 2014; 13: 1065-1076.
64. Behrends V, Williams KJ, Jenkins VA, Robertson BD, Bundy JG. Free glucosylglycerate is a novel marker of nitrogen stress in Mycobacterium smegmatis. J Proteome Res 2012; 11: 3888-3896.
65. Mehta R, Jain RK, Badve S. Personalized medicine: The road ahead. Clin Breast Cancer 2011; 11: 20-26.
66. Sudhindra A, Ochoa R, Santos ES. Biomarkers, prediction, and prognosis in non-small-cell lung cancer: A platform for personalized treatment. Clin Lung Cancer 2011; 12: 360-368.
67. Kumar B, Prakash A, Ruhela RK, Medhi B. Potential of metabolomics in preclinical and clinical drug development. Pharmacol Rep 2014; 66: 956-963.
68. Leichtle AB, Dufour JF, Fiedler GM. Potentials and pitfalls of clinical peptidomics and metabolomics. Swiss Med Wkly 2013; 143: W13801.
69. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005; 3: 431-438.
70. Koek MM, Jellema RH, van der Greef J, Tas AC, Hankemeier T. Quantitative metabolomics based on gas chromatography mass spectrometry: Status and perspectives. Metabolomics 2011; 7: 307-328.
71. Horvatovich PL, Bischoff R. Current technological challenges in biomarker discovery and validation. Eur J Mass Spectrom (Chichester, Eng) 2010; 16: 101-121.
72. Singer M. Biomarkers in sepsis. Curr Opin Pulm Med 2013; 19: 305-309.